Skip to search formSkip to main contentSkip to account menu

cinacalcet

Known as: (R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine, CNC, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (3)

AMG 073Mimparacinacalcet hydrochloride
cinacalcet 90 MG Oral Tablet [Sensipar]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Neonatal Hypercalcemia due to a Homozygous Mutation in the Calcium-Sensing Receptor: Failure of Cinacalcet
A neonate affected by a novel inactivating mutation in the calcium-sensing receptor (CASR) gene is presented. This mutation is… 
2012
2012
Distribution and regulation of the 25-hydroxyvitamin D3 1α-hydroxylase in human parathyroid glands
2010
2010
Cinacalcet Treatment for Secondary Hyperparathyroidism in Dialysis Patients: An Observational Study in Routine Clinical Practice
Background: Cinacalcet reduces intact parathyroid hormone (iPTH), Ca and P serum levels in patients with secondary… 
Highly Cited
2008
Highly Cited
2008
Simple chiral diene ligands provide high enantioselectivities in transition-metal-catalyzed conjugate addition reactions.
Chiral dienes possessing the bicyclo[2.2.2]octadiene framework were prepared readily through the [4 + 2] cycloaddition of ( R… 
Highly Cited
2008
Highly Cited
2008
Cinacalcet reduces the set point of the PTH-calcium curve.
The calcimimetic cinacalcet increases the sensitivity of the parathyroid calcium-sensing receptor to calcium and therefore should… 
2008
2008
Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose.
BACKGROUND In the setting of kidney transplantation, cinacalcet has been given, mainly, once daily, but also twice daily. The… 
2008
2008
Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
BACKGROUND The parathyroid-calcium (Ca(2+)-PTH) curve expresses modulation of parathyroid hormone (PTH) secretion by the… 
Highly Cited
2007
Highly Cited
2007
Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic…
BACKGROUND The purpose of the present study was to evaluate the impact of cinacalcet administration on the attainment of Kidney… 
2006
2006
Cinacalcet as an adjunct in the successful treatment of calciphylaxis
1 Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med… 
2005
2005
Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl
Cinacalcet, a novel calcimimetic compound, is effective in reducing parathyroid hormone (PTH) levels in approximately 70% of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)